NKTR Nektar Therapeutics
USHealthcareAs of 2026-08-24
Why NKTR matters now
Nektar Therapeutics (NKTR) is a US stock in Healthcare. The latest InvestLog snapshot shows $73.69 with -0.45% on the session and $2.11B in market capitalization; recent performance reads 1-month -9.77% and YTD +44.23%.
The latest financial table shown here is Q1 2026, with revenue of $10.9M, net income of $-44.9M, and EPS of $-1.82. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.1%.
The latest indexable market news headline is "Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $151.00; recent insider activity includes ROBIN HOWARD W filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.62
P/S
21.42
EV/EBITDA
-9.55
DCF Value
$-28.60
FCF Yield
-17.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.4%
Operating Margin
-224.9%
Net Margin
-284.2%
ROE
-87.0%
ROA
-20.7%
ROIC
-17.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.9M | $-44.9M | $-1.82 |
| Q4 2025 | $21.8M | $-36.1M | $-1.78 |
| FY 2025 | $55.2M | $-164.1M | $-9.73 |
| Q3 2025 | $11.8M | $-35.5M | $-1.87 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$149.60
Target (Median)
$151.00
Target Range
$80.00 - $192.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.15
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.